Meeting
2021 ASCO Annual Meeting
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
Authors
Dongsheng Yue
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Dongsheng Yue , Shi-Dong Xu , Qun Wang , Xiaofei Li , Yi Shen , Heng Zhao , Chun Chen , Weimin Mao , Wei Liu , Junfeng Liu , Lan-Jun Zhang , Haitao Ma , Qiang Li , Yue Yang , Yongyu Liu , Haiquan Chen , Zhenfa Zhang , Bin Zhang , Fuyu Gong , Changli Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01683175
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8520)
DOI
10.1200/JCO.2021.39.15_suppl.8520
Abstract #
8520
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2012 ASCO Annual Meeting
Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
First Author: Hirohito Tada
Poster
2016 ASCO Annual Meeting
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).
First Author: Jianxing He
Poster
2023 ASCO Annual Meeting
IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.
First Author: Martin Reck